GLP-1 Medications Physician Perspectives: What Endocrinologists and PCPs Are Really Saying in 2026
Introduction: The GLP-1 Conversation Physicians Are Actually Having
The numbers tell a story of unprecedented clinical transformation. GLP-1 prescriptions among non-diabetic patients increased 700% from 2019 to 2023, and today, 12.4% of U.S. adults report taking GLP-1 medications for weight loss—more than double the 5.8% reported just one year ago. This is not simply a pharmaceutical trend; it represents one of the most significant shifts in metabolic medicine in decades.
While consumer media focuses heavily on access barriers and celebrity endorsements, physicians across specialties are navigating a far more complex landscape. Endocrinologists and primary care providers find themselves at the center of unresolved questions about clinical ownership, ethical prescribing boundaries, care coordination, and patient safety.
The core tension is clear: GLP-1 receptor agonists are among the most clinically significant drug classes to emerge in recent memory, yet the infrastructure, training protocols, and inter-specialty frameworks required to manage them responsibly remain works in progress. This article explores four major clinical fault lines currently shaping physician conversations: the specialty ownership debate, telehealth fragmentation concerns, cosmetic-use ethical dilemmas, and the emergence of cross-specialty metabolic care teams.
The State of GLP-1 Prescribing in 2026: A Clinical Snapshot
The current GLP-1 landscape features 11 FDA-approved medications spanning more than five drug types across at least a dozen brands. January 2026 marked a pivotal inflection point with the launch of the Wegovy pill (oral semaglutide 25 mg), while Eli Lilly’s orforglipron—a once-daily oral non-peptide GLP-1—awaits FDA approval in Q2 2026. Physicians anticipate this oral formulation could dramatically expand prescribing beyond specialties traditionally comfortable with injectable therapies.
The market scale reflects this clinical momentum. The global GLP-1 receptor agonist market is valued at approximately $73–101 billion in 2026, with projections reaching $180–315 billion by 2035. North America holds the dominant market share at 55–76%.
A significant legitimization signal came in December 2025 when the World Health Organization conditionally endorsed long-term GLP-1 therapy for obesity and added these medications to its Essential Medicines List for high-risk type 2 diabetes patients. This global endorsement is actively influencing physician conversations in the United States.
The clinical evidence base continues to strengthen. A Lancet Diabetes & Endocrinology meta-analysis of 85,373 participants demonstrated that GLP-1 receptor agonists reduced major adverse cardiovascular events by 13%, kidney failure by 16–18%, and all-cause mortality by 12% in patients with type 2 diabetes. These findings are reshaping how physicians across specialties view these medications—not merely as weight loss drugs, but as agents with profound cardiometabolic implications.
Who Should Own GLP-1 Management? The Endocrinologist vs. PCP Debate
As GLP-1 prescribing spreads across primary care, cardiology, and other specialties, a fundamental question remains unresolved: who bears primary clinical responsibility for these patients?
Survey data reveals a striking tension. Approximately 85.6% of physicians believe primary care providers should be the primary GLP-1 prescribers, yet most PCPs lack formal obesity medicine training—a competency gap that concerns specialists and generalists alike.
Dr. Michael Weintraub of NYU Langone Health has observed “a gap between what obesity medicine specialists know and what primary care doctors—who treat most patients with obesity—are equipped to do.” This recognition has prompted the development of new training initiatives, including an NEJM Group course designed to address these deficiencies.
Endocrinologists express caution about ceding full clinical ownership for substantive reasons. GLP-1 medications require careful titration, proactive side effect management, and ongoing monitoring—characteristics that make them unsuitable for what some physicians describe as “prescription and wave” models where follow-up is minimal.
A joint advisory from four major medical societies—the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society—explicitly flags that most physicians lack formal training in nutrition and lifestyle integration alongside GLP-1 prescribing. This gap has direct clinical consequences.
The practical reality, however, is unavoidable. With 12.4% of U.S. adults now taking GLP-1 medications, endocrinologists cannot absorb the patient volume. PCP upskilling is not optional—it is urgent. Complicating matters further, cost and prior authorization remain the top prescribing barriers across all specialties.
The Training Gap: Why Most PCPs Are Prescribing Without a Full Toolkit
The specific competency gaps are substantial. Most PCPs prescribing GLP-1s have not received formal training in obesity medicine, nutritional counseling integration, or structured lifestyle protocol design.
The clinical consequences are measurable. A UT Southwestern study published in JAMA Network Open in March 2026 found that only 25% of patients remained on any GLP-1 receptor agonist one year after starting therapy. Physicians attribute this discontinuation rate in part to inadequate counseling and follow-up infrastructure.
The joint advisory from the four major medical societies outlines specific clinical priorities that many PCPs are not currently providing: resistance training prescriptions and protein intake recommendations of 1.0–1.2 grams per kilogram of body weight to protect lean mass, particularly in older or frail patients.
Emerging CME initiatives represent early-stage solutions to a systemic problem. Notably, the training gap extends beyond primary care—cardiologists and nephrologists now prescribing GLP-1s for cardiovascular and renal indications face similar knowledge deficits in obesity medicine fundamentals.
Telehealth GLP-1 Prescribing: What Physicians Are Really Thinking
A survey of 2,000 primary care physicians found that 67% believe GLP-1 prescriptions from third-party telehealth providers pose a significant risk to patient health. The concerns center on inadequate medical history reviews and insufficient monitoring protocols.
The disclosure gap compounds these concerns. Sixty-one percent of PCPs report that patients fail to disclose telehealth GLP-1 prescriptions, creating fragmented care scenarios with serious liability and safety implications.
Prescribing comfort levels reflect this skepticism. Only 18% of surveyed PCPs are comfortable with patients obtaining semaglutide-based treatment from a telehealth prescriber, while 57% actively caution patients against it.
Physicians cite specific clinical risks: drug interactions missed due to incomplete histories, absence of baseline laboratory work, no titration oversight, and inadequate contraindication screening. The practical challenge is immediate—patients who have already started a telehealth-prescribed GLP-1 present to their PCP mid-treatment, requiring physicians to determine how to assume care, assess safety, and document appropriately.
In March 2026, the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products, signaling aggressive regulatory enforcement.
Compounded GLP-1s in the Exam Room: A Practical Guide for Physicians
During the semaglutide shortage period, compounded versions proliferated. FDA enforcement is now active, but patients continue to present with these products.
When patients disclose compounded GLP-1 use, physicians should assess several factors: source verification, dosing accuracy, sterility standards, and whether the compounding pharmacy holds 503A or 503B registration. The goal is care continuity, not confrontation—transitioning patients to FDA-approved formulations when clinically appropriate and financially feasible.
The FDA’s March 2026 warning letters provide physicians with a concrete reference point when explaining to patients why regulatory concern is legitimate. Documentation of counseling conversations is essential, as physicians who continue managing patients on compounded GLP-1s without such documentation face potential liability exposure.
When Patients Ask for GLP-1s for Cosmetic Weight Loss: The Ethical Fault Line
Physicians are increasingly receiving requests from patients who are overweight but not obese, or who have BMIs in the normal range, seeking GLP-1 medications for aesthetic rather than medical reasons.
Harvard endocrinologist Dr. Jody Dushay of Beth Israel Deaconess Medical Center has identified a related dilemma: patients seeking to remain on GLP-1s beyond healthy weight thresholds. She has also flagged the rise of disordered eating patterns among GLP-1 users—appetite suppression that crosses into restriction, with psychological dimensions that physicians are beginning to recognize.
The allocation question looms large. In a landscape where cost and supply remain constrained, prescribing to cosmetic-use patients may displace access for patients with serious metabolic disease.
Current data shows that PCPs approve GLP-1 prescription requests 53% of the time on average, with 77% conducting thorough physical evaluations before prescribing and 56% requiring non-pharmacological interventions first. Most physicians are applying gatekeeping, but inconsistently.
The absence of standardized clinical criteria distinguishing cosmetic from medical weight loss prescribing creates both ethical ambiguity and liability exposure. A practical framework involves aligning prescribing decisions with FDA-approved indications, documented comorbidities, and structured shared decision-making conversations that include psychological screening.
Cross-Specialty Coordination: How GLP-1s Are Restructuring Metabolic Care Teams
The cardiovascular and renal benefits of GLP-1s—a 13% reduction in major adverse cardiovascular events and a 16–18% reduction in kidney failure—mean cardiologists and nephrologists now have independent clinical reasons to prescribe or co-manage these medications.
Practical workflow challenges abound: who initiates therapy, who monitors, who manages side effects, and how electronic health records support—or fail to support—coordinated care across specialties. The joint advisory from four major medical societies explicitly calls for nutritional integration, requiring a team-based model most practices have not yet built.
A notable coordination requirement has emerged around surgical procedures. Physicians are implementing temporary GLP-1 discontinuation protocols due to increased pulmonary aspiration risk from GLP-1-induced gastric slowing—a requirement spanning anesthesiology, surgery, and prescribing physicians.
Post-bariatric surgery GLP-1 use represents a growing clinical niche without standardized guidelines, requiring individualized decision-making and close multi-specialty collaboration.
Emerging Indications: What Physicians Need to Know Beyond Diabetes and Obesity
GLP-1s are now being formally studied for Alzheimer’s disease risk reduction, MASH (metabolic-associated steatohepatitis), osteoarthritis, obstructive sleep apnea, peripheral artery disease, and autoimmune conditions.
Physicians are observing anecdotal reductions in alcohol and tobacco use among GLP-1 patients, prompting formal studies on substance use disorders. The muscle loss concern, while often overstated, remains clinically relevant for older or frail patients—research shows GLP-1-induced weight loss does not cause disproportionate muscle loss in middle-aged adults, but resistance training and adequate protein intake remain essential recommendations. Understanding how diet can affect hormones is increasingly relevant as physicians integrate nutritional guidance into GLP-1 management protocols.
Pipeline agents approaching clinical relevance include retatrutide (a triple agonist demonstrating greater than 28% average weight loss), CagriSema (semaglutide combined with cagrilintide), and eloralintide (an amylin analog for patients intolerant of GLP-1 side effects). Emerging evidence also supports combining GLP-1 receptor agonists with SGLT2 inhibitors for enhanced cardiorenal protection.
Access, Cost, and the Medicare BALANCE Model: What Physicians Should Tell Patients
Cost remains the primary discontinuation driver. Dr. Michael Weintraub cites an average out-of-pocket cost of $450 per month as the leading reason patients discontinue GLP-1 therapy.
Starting July 1, 2026, the Medicare BALANCE model will provide eligible Part D enrollees temporary access to select GLP-1s for obesity, with out-of-pocket costs capped at approximately $50 per month through December 2026. Physicians should proactively discuss this option with eligible patients.
The UT Southwestern adherence data offers a notable clinical insight: patients who switched medications showed higher adherence than those who remained on their initial drug. This finding should inform how physicians counsel patients experiencing side effects or suboptimal response.
Oral formulations may reduce injection-related barriers significantly. Prior authorization remains a top barrier across all specialties, requiring physicians to document medical necessity with specificity—including comorbidities, BMI, and prior non-pharmacological intervention attempts. Cost and access conversations should occur at the point of prescribing, not after patients discover the price at the pharmacy.
Conclusion: The Clinical Moment Physicians Cannot Afford to Approach Passively
GLP-1 medications represent one of the most significant clinical opportunities in decades. Realizing their full potential requires physicians to actively engage with the ownership, ethics, coordination, and training challenges this drug class has surfaced.
The decisions that will define GLP-1 outcomes—who prescribes, how care is coordinated, when to decline requests, and how to integrate lifestyle medicine—are being made in exam rooms across the country. Cross-specialty metabolic care teams, standardized telehealth oversight protocols, obesity medicine continuing education, and ethical prescribing frameworks are not optional enhancements. They represent the clinical infrastructure GLP-1 management requires.
As pipeline agents expand the therapeutic landscape and indications extend into neurology, hepatology, and addiction medicine, physicians who invest in building GLP-1 competency now will be best positioned to lead metabolic care in the coming decade. The physical benefits of exercise remain a critical complement to pharmacological treatment, and physicians who can counsel patients on integrating movement with GLP-1 therapy will deliver more comprehensive metabolic care.
Share Your Perspective with Top Doctor Magazine
Physicians, endocrinologists, and primary care providers are invited to contribute their own GLP-1 clinical perspectives, case insights, or practice management strategies to Top Doctor Magazine. Healthcare professionals leading innovative approaches to GLP-1 management, cross-specialty metabolic care, or obesity medicine training are encouraged to seek nomination for a Top Doctor Magazine feature or awards recognition.
Subscribing to the Top Doctor Magazine biweekly newsletter provides ongoing clinical updates, physician profiles, and emerging research coverage in metabolic medicine. The Top Doctor Magazine podcast and webinars offer additional venues where the physician community can continue these conversations in depth.
Visit topdoctormagazine.com to nominate a physician, subscribe to the newsletter, or inquire about editorial features.
